A MAJOR new British study in the Lancet journal claims finally to put to rest the rancorous debate worldwide over the risk-versus-benefit profile of statins. The authors say the evidence is "overwhelming" that statins are safe and effective for primary and secondary prevention — to prevent a first heart attack or stroke in otherwise healthy people, or to prevent a second attack or stroke. Statins are cholesterol-lowering drugs used to treat or prevent heart disease and stroke. They have become the world’s most prescribed drugs and generate billions in revenue for the drug companies that make them. The Lancet review is led by Rory Collins of Oxford University’s clinical trial service unit. It has revived concerns about the serious side effects of statins that include muscle, nerve, liver and cardiovascular damage, endocrine disruption, erectile dysfunction and an increased risk of diabetes, cancer, cataracts and birth defects. Top experts worldwide say the new review is dangerous and...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.